Loading clinical trials...
Loading clinical trials...
A Phase 2a, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
Conditions
Interventions
OK-101 0.05%
OK-101 0.1%
+1 more
Locations
1
United States
Tufts Medical Center
Boston, Massachusetts, United States
Start Date
October 15, 2024
Primary Completion Date
April 30, 2025
Completion Date
July 1, 2025
Last Updated
August 15, 2025
NCT07436806
NCT06726954
NCT07057128
NCT07285018
NCT07293780
NCT07403331
Lead Sponsor
Okyo Pharma Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions